Non small cell lung cancer directional treatment of biological markers: RRM-1, class III beta tubulin and ERCC-1

Lung cancer is the most common cause of cancer deaths in all over the world. Despite the developments in diagnosis and treatment, the high mortality rate in metastatic non small cell lung cancer (NSCLC) is still an important problem. Recent non targeted standard therapy for NSCLC is the dual therapy regimens which involve platins. The first step therapy regimens can cause significant side effects upon all the organ systems. Our former knowledge whether these therapies can be effective or not would save the patient from the redundant toxicity and provide us to use more effective drugs formerly.Understanding the biology of NSCLC can allow choosing the effective and appropriate therapy in terms of life quality, survival rate and relapses. There are ongoing studies upon prognostic and predictive values of ERCC1, RRM1 and ß tubulin in NSCLC patients.In this study we aimed to investigate the role of ß tubulin, ERCC1 and RRM1 expressions as predictive biomarkers.Material and Methods: 47 patients who are on follow up by Bilim University, Medical Oncology Department, were taken to the study. ? tubulin, ERCC1 and RRM1 over expressions were investigated in the biopsy materials of these patients by the Pathology Department. Retrospectively, it was evaluated whether there is correlation between these biological markers and patients? survial rates and responses to antineoplastic therapies.